Reduction seen in cardiovascular events irrespective of baseline HbA1c or change in HbA1c
Read More »Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
Patients with overweight, obesity receiving tirzepatide significantly more likely to achieve ≥5, ≥10, and ≥15 percent weight loss
Read More »American Diabetes Association, June 21-24
By Beth Gilbert HealthDay ReporterThe annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in diabetes. The conference highlighted the latest advances …
Read More »Few With Type 2 Diabetes Receive Guideline-Recommended CKD Screening
24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening
Read More »ADA: Bisphenol A Linked to Reduced Peripheral Insulin Sensitivity
Significant decrease seen in peripheral insulin sensitivity with four-day energy balance diet plus oral BPA administration
Read More »ADA: Inhaled Insulin Shows Promise for Adults With Type 1 Diabetes
Authors say inhaled insulin may provide convenient alternative delivery method
Read More »ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart Failure
Semaglutide reduces body weight to a greater extent in females; yields similar improvements in heart failure-related symptoms in both sexes
Read More »ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points
Read More »Dysbiosis in Phylogenetically Diverse Species Associated With Type 2 Diabetes
Within-species phylogenetic diversity identified for strains of 27 species that explain inter-individual differences in type 2 diabetes risk
Read More »Intermittent Fasting Aids Early Diabetes Outcomes More Than Drugs
Benefits include improved glycemic outcomes and weight loss at 16 weeks in the short term compared with metformin or empagliflozin
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.